Amplia Therapeutics halted recruitment in its Phase II Amplicity trial in advanced pancreatic cancer after three dose-limiting toxicities linked to the chemotherapy backbone combined with narmafotinib. The regimen uses modified FOLFIRINOX alongside AMP-945, a focal adhesion kinase inhibitor. The company stopped enrollment while it evaluates the cause and potential mitigation steps for the toxicities observed. No effectiveness conclusions were stated as the trigger was a safety event during dose evaluation. For sponsors watching translational FAK/chemotherapy combinations, the move underscores the continuing trial volatility in pancreatic cancer while dose-limiting events reshape near-term timelines for efficacy assessments.